Harmony Biosciences Acquires Epygenix Therapeutics

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. agreed to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer of $1.1059 per share (approximately $60 million) plus one contingent value right (CVR) per share for up to $140 million of milestone-based payments (total potential consideration up to $200 million). The transaction, unanimously approved by both boards, is expected to close in Q4 2023 and will add Zynerba’s synthetic transdermal cannabidiol candidate Zygel and related rare neuropsychiatric programs to Harmony’s pipeline.

Ipsen Acquires Epizyme

August 12, 2022

Biotechnology

Ipsen has completed the acquisition of Epizyme, Inc., acquiring all outstanding shares for $1.45 per share plus a $1.00 contingent value right and bringing Epizyme's approved oncology drug Tazverik and preclinical/clinical pipeline into Ipsen. The deal adds epigenetics-focused assets including the approved EZH2 inhibitor tazemetostat and the SETD2 inhibitor candidate EZM0414 to Ipsen's oncology portfolio and integrates Epizyme employees into Ipsen's organization.

Kyruus Acquires Epion Health

September 13, 2022

Healthcare Services

Kyruus, a provider search and scheduling platform, has acquired Epion Health, a digital patient engagement company based in Hoboken, New Jersey. The deal combines Kyruus's provider search and scheduling capabilities with Epion's pre-visit intake, patient engagement, and payment tools to create an end-to-end patient access and engagement offering for health systems and medical groups.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.